Which has stronger valuation & earnings, PEPG or IPSC?

Century Therapeutics is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PepGen N/A N/A -$89.65M -$1.75 N/A Century Therapeutics N/A N/A -$9.58M -$1.14 N/A

Is PEPG or IPSC more profitable?

Century Therapeutics' return on equity of -49.89% beat PepGen's return on equity. Company Net Margins Return on Equity Return on Assets PepGen N/A -59.89% -49.62% Century Therapeutics N/A -49.89% -37.42%

Do analysts recommend PEPG or INDP?

PepGen presently has a consensus target price of $11.50, indicating a potential upside of 531.87%. Given PepGen's stronger consensus rating and higher possible upside, equities research analysts plainly believe PepGen is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PepGen 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, PEPG or INDP?

PepGen is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PepGen N/A N/A -$89.65M -$1.75 N/A Indaptus Therapeutics N/A N/A -$20.85M -$15.40 N/A

Is PEPG or INDP more profitable?

PepGen's return on equity of -59.89% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PepGen N/A -59.89% -49.62% Indaptus Therapeutics N/A -1,030.07% -299.69%

Do analysts prefer PEPG or CGC?

PepGen presently has a consensus target price of $11.50, indicating a potential upside of 531.87%. Given PepGen's stronger consensus rating and higher possible upside, equities research analysts plainly believe PepGen is more favorable than Canopy Growth. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PepGen 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Canopy Growth 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17

Is PEPG or CGC more profitable?

PepGen has a net margin of 0.00% compared to Canopy Growth's net margin of -75.27%. Canopy Growth's return on equity of -26.95% beat PepGen's return on equity. Company Net Margins Return on Equity Return on Assets PepGen N/A -59.89% -49.62% Canopy Growth -75.27% -26.95% -17.20%

Which has better valuation & earnings, MNPR or PEPG?

Monopar Therapeutics is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Monopar Therapeutics N/A N/A -$13.72M -$1.90 N/A PepGen N/A N/A -$89.65M -$1.75 N/A

Is MNPR or PEPG more profitable?

Monopar Therapeutics' return on equity of -12.84% beat PepGen's return on equity. Company Net Margins Return on Equity Return on Assets Monopar Therapeutics N/A -12.84% -12.57% PepGen N/A -59.89% -49.62%

Which has preferable valuation & earnings, EPRX or PEPG?

Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eupraxia Pharmaceuticals N/A N/A -$38.58M -$1.05 N/A PepGen N/A N/A -$89.65M -$1.75 N/A

Is EPRX or PEPG more profitable?

PepGen's return on equity of -59.89% beat Eupraxia Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eupraxia Pharmaceuticals N/A -87.56% -51.20% PepGen N/A -59.89% -49.62%

PepGen (PEPG) Competitors

$1.82 -0.01 (-0.55%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$1.84 +0.02 (+0.88%)

As of 08:42 AM Eastern

Compare

PEPG vs. IPSC, INDP, CGC, MNPR, and EPRX

Should you buy PepGen stock or one of its competitors? MarketBeat compares PepGen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PepGen include Century Therapeutics (IPSC), Indaptus Therapeutics (INDP), Canopy Growth (CGC), Monopar Therapeutics (MNPR), and Eupraxia Pharmaceuticals (EPRX). These companies are all part of the "pharmaceutical products" industry.

How does PepGen compare to Century Therapeutics?

PepGen (NASDAQ:PEPG) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Century Therapeutics' return on equity of -49.89% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-59.89%	-49.62%
Century Therapeutics	N/A	-49.89%	-37.42%

58.0% of PepGen shares are held by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are held by institutional investors. 1.3% of PepGen shares are held by insiders. Comparatively, 2.4% of Century Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Century Therapeutics is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A
Century Therapeutics	N/A	N/A	-$9.58M	-$1.14	N/A

In the previous week, PepGen's average media sentiment score of 0.00 equaled Century Therapeutics'average media sentiment score.

Company	Overall Sentiment
PepGen	Neutral
Century Therapeutics	Neutral

PepGen currently has a consensus price target of $11.50, indicating a potential upside of 531.87%. Century Therapeutics has a consensus price target of $4.75, indicating a potential upside of 97.10%. Given PepGen's stronger consensus rating and higher probable upside, equities analysts plainly believe PepGen is more favorable than Century Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

PepGen has a beta of 1.93, indicating that its share price is 93% more volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.56, indicating that its share price is 56% more volatile than the broader market.

Summary

PepGen beats Century Therapeutics on 6 of the 11 factors compared between the two stocks.

How does PepGen compare to Indaptus Therapeutics?

PepGen (NASDAQ:PEPG) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

PepGen has a beta of 1.93, indicating that its share price is 93% more volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market.

PepGen's return on equity of -59.89% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-59.89%	-49.62%
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%

PepGen is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A

58.0% of PepGen shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 1.3% of PepGen shares are owned by insiders. Comparatively, 23.6% of Indaptus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Indaptus Therapeutics had 2 more articles in the media than PepGen. MarketBeat recorded 2 mentions for Indaptus Therapeutics and 0 mentions for PepGen. Indaptus Therapeutics' average media sentiment score of 0.46 beat PepGen's score of 0.00 indicating that Indaptus Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
PepGen	Neutral
Indaptus Therapeutics	Neutral

PepGen presently has a consensus target price of $11.50, indicating a potential upside of 531.87%. Given PepGen's stronger consensus rating and higher possible upside, equities research analysts plainly believe PepGen is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

PepGen beats Indaptus Therapeutics on 8 of the 13 factors compared between the two stocks.

How does PepGen compare to Canopy Growth?

PepGen (NASDAQ:PEPG) and Canopy Growth (NASDAQ:CGC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

PepGen has a net margin of 0.00% compared to Canopy Growth's net margin of -75.27%. Canopy Growth's return on equity of -26.95% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-59.89%	-49.62%
Canopy Growth	-75.27%	-26.95%	-17.20%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Canopy Growth	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

PepGen has higher earnings, but lower revenue than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A
Canopy Growth	$251.01M	1.52	-$190.29M	-$0.59	N/A

58.0% of PepGen shares are owned by institutional investors. Comparatively, 3.3% of Canopy Growth shares are owned by institutional investors. 1.3% of PepGen shares are owned by company insiders. Comparatively, 0.2% of Canopy Growth shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

PepGen has a beta of 1.93, meaning that its share price is 93% more volatile than the broader market. Comparatively, Canopy Growth has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

In the previous week, Canopy Growth had 9 more articles in the media than PepGen. MarketBeat recorded 9 mentions for Canopy Growth and 0 mentions for PepGen. Canopy Growth's average media sentiment score of 0.04 beat PepGen's score of 0.00 indicating that Canopy Growth is being referred to more favorably in the news media.

Company	Overall Sentiment
PepGen	Neutral
Canopy Growth	Neutral

Summary

PepGen beats Canopy Growth on 9 of the 15 factors compared between the two stocks.

How does PepGen compare to Monopar Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

In the previous week, Monopar Therapeutics had 1 more articles in the media than PepGen. MarketBeat recorded 1 mentions for Monopar Therapeutics and 0 mentions for PepGen. Monopar Therapeutics' average media sentiment score of 0.63 beat PepGen's score of 0.00 indicating that Monopar Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Monopar Therapeutics	Positive
PepGen	Neutral

1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 58.0% of PepGen shares are owned by institutional investors. 9.7% of Monopar Therapeutics shares are owned by company insiders. Comparatively, 1.3% of PepGen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Monopar Therapeutics presently has a consensus price target of $107.91, suggesting a potential upside of 31.48%. PepGen has a consensus price target of $11.50, suggesting a potential upside of 531.87%. Given PepGen's higher probable upside, analysts clearly believe PepGen is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Monopar Therapeutics has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market. Comparatively, PepGen has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market.

Monopar Therapeutics' return on equity of -12.84% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-12.84%	-12.57%
PepGen	N/A	-59.89%	-49.62%

Monopar Therapeutics is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A

Summary

Monopar Therapeutics beats PepGen on 9 of the 14 factors compared between the two stocks.

How does PepGen compare to Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

58.0% of PepGen shares are owned by institutional investors. 1.3% of PepGen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Eupraxia Pharmaceuticals had 3 more articles in the media than PepGen. MarketBeat recorded 3 mentions for Eupraxia Pharmaceuticals and 0 mentions for PepGen. Eupraxia Pharmaceuticals' average media sentiment score of 0.52 beat PepGen's score of 0.00 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Eupraxia Pharmaceuticals	Positive
PepGen	Neutral

Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A

Eupraxia Pharmaceuticals presently has a consensus price target of $18.33, suggesting a potential upside of 186.91%. PepGen has a consensus price target of $11.50, suggesting a potential upside of 531.87%. Given PepGen's higher probable upside, analysts plainly believe PepGen is more favorable than Eupraxia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Eupraxia Pharmaceuticals has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, PepGen has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market.

PepGen's return on equity of -59.89% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%
PepGen	N/A	-59.89%	-49.62%

Summary

PepGen beats Eupraxia Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get PepGen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PEPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PEPG vs. The Competition

Export

Metric	PepGen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$125.89M	$3.45B	$6.44B	$12.30B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-1.04	19.75	24.66	23.99
Price / Sales	N/A	329.51	531.91	108.06
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	0.85	8.29	10.81	6.50
Net Income	-$89.65M	$23.85M	$3.56B	$336.88M
7 Day Performance	7.06%	2.87%	0.93%	-0.16%
1 Month Performance	20.53%	2.19%	0.35%	0.76%
1 Year Performance	30.94%	55.48%	29.69%	28.49%

PepGen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PEPG PepGen	2.3806 of 5 stars	$1.82 -0.5%	$11.50 +531.9%	+30.9%	$125.89M	N/A	N/A	30	Gap Down
IPSC Century Therapeutics	1.6588 of 5 stars	$2.30 +2.2%	$4.75 +106.5%	+319.1%	$405.80M	$109.16M	N/A	170
INDP Indaptus Therapeutics	1.1199 of 5 stars	$3.69 +3.1%	N/A	-73.5%	$405.41M	N/A	N/A	6	Gap Down
CGC Canopy Growth	1.4723 of 5 stars	$0.98 -1.7%	N/A	-20.5%	$404.12M	$225.65M	N/A	3,150	Trending News Insider Trade
MNPR Monopar Therapeutics	1.9454 of 5 stars	$61.47 +2.8%	$107.91 +75.5%	+157.8%	$400.40M	N/A	N/A	10	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PEPG) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PepGen (PEPG) Competitors

PEPG vs. IPSC, INDP, CGC, MNPR, and EPRX

How does PepGen compare to Century Therapeutics?

Summary

How does PepGen compare to Indaptus Therapeutics?

Summary

How does PepGen compare to Canopy Growth?

Summary

How does PepGen compare to Monopar Therapeutics?

Summary

How does PepGen compare to Eupraxia Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PEPG vs. The Competition

PepGen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PepGen (PEPG) Competitors

PEPG vs. IPSC, INDP, CGC, MNPR, and EPRX

How does PepGen compare to Century Therapeutics?

Is PEPG or IPSC more profitable?

Do insiders & institutionals believe in PEPG or IPSC?

Which has stronger valuation & earnings, PEPG or IPSC?

Does the media favor PEPG or IPSC?

Do analysts rate PEPG or IPSC?

Which has more risk & volatility, PEPG or IPSC?

Summary

How does PepGen compare to Indaptus Therapeutics?

Which has more volatility and risk, PEPG or INDP?

Is PEPG or INDP more profitable?

Which has higher earnings & valuation, PEPG or INDP?

Do institutionals and insiders believe in PEPG or INDP?

Does the media refer more to PEPG or INDP?

Do analysts recommend PEPG or INDP?

Summary

How does PepGen compare to Canopy Growth?

Is PEPG or CGC more profitable?

Do analysts prefer PEPG or CGC?

Which has higher valuation and earnings, PEPG or CGC?

Do insiders & institutionals have more ownership in PEPG or CGC?

Which has more risk and volatility, PEPG or CGC?

Does the media favor PEPG or CGC?

Summary

How does PepGen compare to Monopar Therapeutics?

Does the media refer more to MNPR or PEPG?

Do institutionals and insiders hold more shares of MNPR or PEPG?

Do analysts prefer MNPR or PEPG?

Which has more volatility and risk, MNPR or PEPG?

Is MNPR or PEPG more profitable?

Which has better valuation & earnings, MNPR or PEPG?

Summary

How does PepGen compare to Eupraxia Pharmaceuticals?

Do insiders and institutionals hold more shares of EPRX or PEPG?

Does the media prefer EPRX or PEPG?

Which has preferable valuation & earnings, EPRX or PEPG?

Do analysts rate EPRX or PEPG?

Which has more risk and volatility, EPRX or PEPG?

Is EPRX or PEPG more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PEPG vs. The Competition

PepGen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools